Clinical trials
HER2 + Breast Cancer clinical trials
Below are recruiting her2 + breast cancer clinical trials, each written for real people, not researchers. We’re tracking 956 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06705127RecruitingPhase 2
Radiation, chemo, and immunotherapy for HR+ breast cancer
This trial tests if giving radiation first, then chemo with an immunotherapy drug called Toripalimab, can help treat a certain type of breast cancer that has not spread to other organs. It is for people with hormone receptor positive, HER2 negative breast cancer that is growing fast.
Hangzhou, ZhejiangAges 18–75 - NCT06750484RecruitingPhase 2
Testing trastuzumab deruxtecan in HER2-zero breast cancer
This trial tests a new drug called trastuzumab deruxtecan (a targeted antibody-drug combination) for people with advanced breast cancer that never showed any HER2 protein (HER2-zero). The goal is to see if it can shrink tumors and improve outcomes for those who have already had standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT06498154RecruitingPhase 2
Skipping breast surgery for some patients after chemo
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
TianjinAges 18–70 - NCT07394218RecruitingPhase 2
Tumor DNA Blood Test to Guide Breast Cancer Treatment
This trial tests whether using a blood test for tumor DNA can help doctors decide the best treatment for people with HER2-negative breast cancer that has spread. It focuses on a type of therapy called an antibody-drug conjugate (ADC) and aims to personalize your care.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT04469296Recruiting
Diet changes before surgery for hormone-receptor breast cancer
This trial tests whether changing your diet before your breast surgery can help people with early, hormone-receptor (ER/PR+) breast cancer. It focuses on patients who have not started treatment yet and want to keep surgery as the main treatment.
Montpellier, HeraultAges 18–80 - NCT07748598Recruiting
Brain scan monitoring for HER2-positive breast cancer
This study is testing regular MRI brain scans to find any brain metastases early in people with HER2-positive breast cancer that has spread. It aims to see if early detection can help guide treatment and improve outcomes.
LiverpoolAges 16 years+ - NCT05283330RecruitingPhase 1
Tested 212Pb imaging drug for certain advanced GRPR tumors
This early-phase study tests how safe and tolerable an experimental radiation drug is for adults with certain advanced or metastatic cancers that show a target called GRPR. Doctors will also use special scans to confirm the tumor has the target so the treatment can be delivered to the right place.
Chicago, IllinoisAges 18 years+ - NCT07586215Recruiting
HER2-targeted PET imaging to predict treatment response in advanced breast cancer
This trial tests whether a special type of PET scan can predict how well a targeted cancer drug (T-DXd) will work for patients with advanced breast cancer that has specific HER2 markers. The goal is to help doctors personalize treatment decisions based on imaging results.
ShanghaiAges 18 years+ - NCT07069595RecruitingPhase 2
Blood test for breast cancer survivors at risk of recurrence
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
Chapel Hill, North CarolinaAges 18 years+ - NCT06548919Recruiting
Treatment patterns for ESR1-mutated advanced breast cancer
This study looks at how Chinese patients with a specific gene change (ESR1 mutation) in ER-positive, HER2-negative advanced breast cancer are currently being treated. It will help doctors understand what treatments work best for people whose cancer has stopped responding to hormone therapy.
Suzhou, JiangsuAges 18 years+ - NCT06225505Recruiting
Early detection of triple-negative breast cancer return
This trial uses blood tests to look for signs of cancer returning early in women who had triple-negative breast cancer. If caught early, doctors can start treatment sooner.
AvignonAges 18 years+ - NCT03804944RecruitingPhase 2
Vaccine trial for hormone-positive breast cancer
This Phase 2 study tests an individualized vaccine made from your tumor information to help your immune system fight hormone-positive breast cancer. You may be able to participate if you meet specific hormone-receptor, health, and treatment-timing requirements.
Los Angeles, CaliforniaAges 18–90 - NCT03990896RecruitingPhase 2
Talazoparib for metastatic breast cancer with BRCA body DNA changes
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
San Francisco, CaliforniaAges 18 years+ - NCT04677816RecruitingPhase 2
Vitamin D supplements for triple-negative breast cancer before surgery
This trial tests whether taking high-dose vitamin D during pre-surgery (neoadjuvant) chemotherapy can increase the chance of having no remaining cancer found at surgery. It focuses on people with vitamin D deficiency and triple-negative breast cancer.
Winston-Salem, North CarolinaAges 18 years+ - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Lake Mary, FloridaAges 18 years+ - NCT04925856Recruiting
Monitoring the immune system during breast cancer drug treatment
This study looks at how your immune system changes while you receive standard breast cancer treatments. The researchers measure immune-related signals during your treatment to better understand what may be happening in triple-negative or certain hormone-receptor breast cancers.
BesançonAges 18–85 - NCT06976944RecruitingPhase 2
Pembrolizumab, Paclitaxel, and Bevacizumab for Triple-Negative Breast Cancer
This trial tests a combination of the immunotherapy drug pembrolizumab, the chemotherapy paclitaxel, and possibly the targeted drug bevacizumab for people with triple-negative breast cancer that has returned after treatment. It aims to see if adding bevacizumab improves outcomes for patients whose tumors are PD-L1 positive.
Nagoya, Aichi-kenAges 18 years+ - NCT05212454RecruitingPhase 3
Capecitabine added after surgery for high-risk ER-positive breast cancer
This Phase 3 study tests whether adding capecitabine (a chemotherapy pill) after breast cancer surgery can lower the chance the cancer comes back. It targets people with hormone-receptor–positive and HER2-negative breast cancer who are considered “high risk.”
Hanzhou, ZhejiangAges 18–70 - NCT05766410RecruitingPhase 2
Testing three CDK4/6 pills to change the immune response
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
TaipeiAges 20 years+ - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05891093RecruitingPhase 3
Fluzoparib plus hormone therapy after surgery for breast cancer
This Phase 3 trial tests whether fluzoparib added to standard hormone (endocrine) therapy after early breast cancer surgery can improve outcomes and safety. It may help patients whose tumors are ER-positive, HER2-negative, and a specific SNF3 subtype.
Beijing, Beijing MunicipalityAges 18–70 - NCT05914961Recruiting
Tracking inflammation response in triple-negative breast cancer
This trial studies how a blood inflammation marker (CRP) changes after starting immunotherapy plus chemotherapy in people with triple-negative breast cancer. Results may help doctors predict who benefits from treatment and when.
TübingenAges 18 years+ - NCT06299202Recruiting
Predicting breast cancer treatment response with special mammogram
This study uses a special type of mammogram with contrast dye to see if it can predict how well breast cancer responds to chemotherapy before surgery. It's for people with HER2-positive or triple-negative breast cancer.
LyonAges 35 years+ - NCT06387628RecruitingPhase 2
LM-108 with immunotherapy for advanced triple-negative breast cancer
This trial tests a new drug called LM-108 combined with a PD-1 inhibitor (a type of immunotherapy) for people with triple-negative breast cancer that has come back or spread. It aims to see if this combination can help shrink tumors or slow the disease.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 + breast cancer?
- Yes. Clin2 currently lists 956 recruiting her2 + breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 + breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.